Mayzent for the treatment of adult patients with active secondary progressive multiple sclerosis: CHMP has granted positive opinion
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion for Mayzent ( Siponimod ) for the treatment of adult patients with s ...
read article